FDA-cleared profile

aPROMISE

EXINI Diagnostics AB

aPROMISE is a cloud-based platform for healthcare professionals and researchers to accept, transfer, store, display, manipulate, quantify, and report PSMA PET/CT examinations using the PROMISE framework.

Evidence status: each field shows source quality, applicability, and review date. Research pending, information not established in reviewed sources, and vendor documentation pending are distinct outcomes.

Clinical fit

What this tool is for

Start with the authorized purpose, then verify how it fits your service line and reading workflow.

Exact purpose
aPROMISE is a cloud-based platform for healthcare professionals and researchers to accept, transfer, store, display, manipulate, quantify, and report PSMA PET/CT examinations using the PROMISE framework.
FDA source Exact FDA submission Checked 2026-09-03
Intended users
Qualified nuclear medicine physicians, radiologists, and trained imaging analysts.
FDA source Exact FDA submission Checked 2026-09-03
Care setting and population
Molecular-imaging departments or validated research workflows using supported DICOM PET/CT examinations.
FDA source Exact FDA submission Checked 2026-09-03
Workflow role
PET/CT visualization, segmentation, quantification, quality control, and structured reporting support.
FDA source Exact FDA submission Checked 2026-09-03
Required input
Supported DICOM PET/CT studies, radiopharmaceutical metadata, and user-confirmed regions of interest.
FDA source Exact FDA submission Checked 2026-09-03
Output and human action
Visualizations, segmentations, measurements, quantitative disease-burden results, and reports for professional confirmation.
FDA source Exact FDA submission Checked 2026-09-03
Limitations
Quantification depends on tracer, acquisition, reconstruction, segmentation, image quality, and user quality-control steps; candidate literature and current family materials do not establish exact-version performance unless explicitly linked to the submission.
FDA source Exact FDA submission Checked 2026-09-03

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K211655
FDA source Exact FDA submission Checked 2026-08-31
Modality
PET/SPECT/Nuclear Medicine
FDA source Exact FDA submission Checked 2026-09-03
Anatomy
Prostate
FDA source Exact FDA submission Checked 2026-09-03
Clearance type
510(k)
FDA source Exact FDA submission Checked 2026-08-31
Decision date
2021-07-27
FDA source Exact FDA submission Checked 2026-08-31
FDA status
FDA-cleared
FDA source Exact FDA submission Checked 2026-08-31

Implementation

Questions for IT, informatics, and operations

Use these fields to structure a vendor demo, security review, and implementation estimate.

Integration
K211655 describes DICOM transfer, a four-panel PET/CT/fusion/MIP display, ROI quantification, user quality control, electronic report confirmation, and archival workflow. Current EXINI or PYlarify material is product-family context and does not prove the exact deployed cloud configuration.
Public source Product family Checked 2026-09-03

Current vendor materials are product-family evidence for K211655; confirm the exact cleared version, enabled options, deployment, and local compatibility.

Deployment and data flow
Cloud-based web platform as described in K211655; confirm hosting region, tenant isolation, identity, retention, and current product build with the vendor.
Public source Product family Checked 2026-09-03

Current vendor materials are product-family evidence for K211655; confirm the exact cleared version, enabled options, deployment, and local compatibility.

Security and privacy
Vendor documentation pending
Vendor confirmation Exact FDA submission Checked 2026-09-03

Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.

Training and support
Only qualified nuclear medicine physicians, radiologists, and trained imaging analysts should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
FDA source Exact FDA submission Checked 2026-09-03
Monitoring and change control
Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Quantification depends on tracer, acquisition, reconstruction, segmentation, image quality, and user quality-control steps; candidate literature and current family materials do not establish exact-version performance unless explicitly linked to the submission.
Public source Product family Checked 2026-09-03

Current vendor materials are product-family evidence for K211655; confirm the exact cleared version, enabled options, deployment, and local compatibility.

Release and scope verification

Map the installed model, build, options, population, anatomy, inputs, outputs, and enabled AI functions to K211655 before acceptance.

exact submission · checked 2026-09-03

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

K211655 describes DICOM transfer, a four-panel PET/CT/fusion/MIP display, ROI quantification, user quality control, electronic report confirmation, and archival workflow. Current EXINI or PYlarify material is product-family context and does not prove the exact deployed cloud configuration.

product family · checked 2026-09-03

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally. Vendor statements are current product-family context; confirm the exact cleared release and installed options.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Quantification depends on tracer, acquisition, reconstruction, segmentation, image quality, and user quality-control steps; candidate literature and current family materials do not establish exact-version performance unless explicitly linked to the submission.

exact submission · checked 2026-09-03

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-03

No exact-product price was found in the reviewed public material; vendor productivity claims are scenario inputs, not guaranteed local savings.

Lifecycle monitoring

Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Quantification depends on tracer, acquisition, reconstruction, segmentation, image quality, and user quality-control steps; candidate literature and current family materials do not establish exact-version performance unless explicitly linked to the submission.

product family · checked 2026-09-03

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. Vendor statements are current product-family context; confirm the exact cleared release and installed options.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version.

Evidence summary
K211655 reports phantom validation, predicate comparison, analytical performance, and a clinical study comparing platform-supported PSMA PET/CT quantification with clinician assessment. The FDA summary does not provide one universal sensitivity or specificity value; exact tracer, acquisition, and version applicability must be checked before using candidate publications as performance evidence.
FDA source Exact FDA submission Checked 2026-09-03
Reported sensitivity
Not applicable
Not applicable Not applicable Checked 2026-09-03

Sensitivity is not the primary endpoint for this system, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.

Reported specificity
Not applicable
Not applicable Not applicable Checked 2026-09-03

Specificity is not the primary endpoint for this system, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K211655 FDA performance package for aPROMISE

Manufacturer phantom, analytical, predicate-comparison, and clinical performance validation · PSMA PET/CT examinations for prostate-cancer imaging, quantification, and structured reporting

exact submission · Tested version: aPROMISE · Sponsor or vendor study

K211655

Manufacturer evidence submitted for FDA clearance or approval; local clinical, technical, and workflow acceptance remains necessary.

PSMA PET Evaluation with a Deep Learning Platform Compared with a Standard Image Viewer and Histopathology.

Peer-reviewed literature candidate identified by exact-name search; full product and version applicability review pending · Prostate or related PET/SPECT/Nuclear Medicine workflow; exact product and version linkage not established

product family · Tested version: Candidate source; exact FDA submission and product version not established · Independence not established

41101977

Candidate source was found by automated exact-name search; product or version linkage and clinical endpoint were not independently established, so it must not be treated as exact-submission performance evidence.

Comparison of diagnostic performance between manual diagnosis following PROMISE V2 and aPROMISE utilizing Ga/F-PSMA PET/CT.

Peer-reviewed literature candidate identified by exact-name search; full product and version applicability review pending · Prostate or related PET/SPECT/Nuclear Medicine workflow; exact product and version linkage not established

product family · Tested version: Candidate source; exact FDA submission and product version not established · Independence not established

40665093

Candidate source was found by automated exact-name search; product or version linkage and clinical endpoint were not independently established, so it must not be treated as exact-submission performance evidence.

Quantitative assessment of PSMA PET response to therapy in castration-sensitive prostate cancer using an automated imaging platform for disease identification and measurement.

Peer-reviewed literature candidate identified by exact-name search; full product and version applicability review pending · Prostate or related PET/SPECT/Nuclear Medicine workflow; exact product and version linkage not established

product family · Tested version: Candidate source; exact FDA submission and product version not established · Independence not established

37009941

Candidate source was found by automated exact-name search; product or version linkage and clinical endpoint were not independently established, so it must not be treated as exact-submission performance evidence.

Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC

ClinicalTrials.gov candidate identified by exact-name search; full product and version applicability review pending · Prostate or related PET/SPECT/Nuclear Medicine workflow; exact product and version linkage not established

product family · Tested version: Candidate source; exact FDA submission and product version not established · Independence not established

NCT07084909

Candidate source was found by automated exact-name search; product or version linkage and clinical endpoint were not independently established, so it must not be treated as exact-submission performance evidence.

Economics and lifecycle

Budget and ongoing governance

These are common procurement questions; unknown values remain visible until a source supports them.

Pricing and total cost
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-03

No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

Reimbursement and coding
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
Public source Not applicable Checked 2026-09-03

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance or approval.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K211655 by exact submission identifier. This does not exclude product-family, later, or adverse-event information.
Public source Exact FDA submission Checked 2026-09-03

Exact-identifier review does not prove absence of all product-family safety signals.

Buyer worksheet

Open questions to take to the vendor

Open evaluation checklist

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
25Fields reviewed
11Source classes checked
9Unreviewed PubMed leads
1Unreviewed trial leads
0Unreviewed FDA recall leads

Recovered from the prior exact-submission extraction and normalized under the current provenance rules. Exact FDA decision materials were reviewed for identity, indication, users, workflow, limitations, and submitted performance. Current vendor material is labeled product-family context where it does not establish the exact release. PubMed and ClinicalTrials.gov results are retained as candidate evidence with version applicability pending; CMS reimbursement context and exact-identifier openFDA postmarket results were also checked. Pricing, final security architecture, contracted services, enabled options, and local interoperability remain organization-specific evidence. Automated exact-name discovery found 9 PubMed and 1 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads remain unpublished until a human confirms the exact product and tested version.

Source classes: fda ai list, fda decision summary, fda decision material, vendor product page, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall

Sources

Source ledger

Sources accessed through 2026-09-03.

Alternatives

Related tools to compare

FDA-cleared K221680

Xeleris V Processing and Review System

GE Healthcare

The Xeleris V Processing and Review System displays, processes, archives, prints, reports, and networks planar, SPECT, and PET nuclear-medicine data, with optional applications...

Modality
PET/SPECT/Nuclear Medicine
Anatomy
Whole body, lung, brain, liver, cardiac, coronary, and other anatomy represented in labeled nuclear-medicine studies
Decision
2023-03-01
FDA-cleared K251153

Aurora

GE Medical Systems Israel

Aurora is a SPECT/CT system for nuclear-medicine uptake imaging, standalone CT, anatomical localization, attenuation correction, diagnosis, staging, therapy planning, guidance,...

Modality
PET/SPECT/Nuclear Medicine
Anatomy
Multi-region
Decision
2025-06-12
FDA-cleared K241585

uMI Panorama

Shanghai United Imaging Healthcare Co.,Ltd.

uMI Panorama GS combines 148 cm axial-field-of-view PET with CT for qualified healthcare professionals across diagnostic, staging, treatment-planning, and response workflows; this...

Modality
PET/SPECT/Nuclear Medicine
Anatomy
Multi-region
Decision
2024-08-30